Warning letterPosted June 2, 2026
FDA warning letter to HealthPartners Neuroscience Center Research and Innovation
Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies
FDA posted a warning letter to HealthPartners Neuroscience Center Research and Innovation on June 2, 2026; the letter is dated May 19, 2026. Subject: Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies. Issuing office: Center for Drug Evaluation and Research (CDER).
On the record
- Company
- HealthPartners Neuroscience Center Research and Innovation
- Subject
- Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Letter dated
- 2026-05-19
- Posted by FDA
- 2026-06-02
- Source
- FDA warning letters ↗
CFR cited
The record cites 5 sections of 21 CFR Part 58.
The full record
An account shows the violations FDA described and each CFR section it cited.
What a warning letter is
A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.
More
Watch HealthPartners Neuroscience Center Research and Innovation
A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA warning letters. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with HealthPartners Neuroscience Center Research and Innovation.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.